Tirosint is approved as a replacement or supplemental therapy for hypothyroidism. While the Facebook page makes suggestions regarding the use of Tirosint for patients with hypothyroidism, it fails to convey that Tirosin is not indicated for transient hypothyroidism during the recovery phase of subacute thyroiditis.
FDA requests that IBSA immediately discontinue the use of the misleading material on the Facebook page and respond to the FDA in writing on or before March 10, 2014.
[1] FDA NDA #021924 TIROSINT (levothyroxine sodium) capsules, for oral use MA #42, Reference ID: 3461139 (2/24/2014).